Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US.
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2014
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Sanofi
- 18 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 May 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 18 May 2010 Actual patient number (260) added as reported by ClinicalTrials.gov.